Idrofos

Idrofos (Ibandronate 150 mg) — Sun Pharma monthly oral bisphosphonate for osteoporosis and bone metastases. Strict empty-stomach upright-30-min dosing rule.

SKU: Idrofos Категория: Anti Cancer Medication, Category Overview, Chronic Conditions

✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026

Encrypted checkout

Crypto pays 10% less

Discreet worldwide delivery

1,400+ customers · 50+ countries

Quick Answer

Idrofos — Ibandronate 150 mg (Sun Pharma). Bisphosphonate — for cancer-related bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia, Paget’s disease, and severe osteoporosis. oral.

What you get with MedsBase:

WHO-GMP certified manufacturer
Discreet plain-envelope packaging
Worldwide shipping
Rated by 1,400+ customers (read reviews)

📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.

Why order from MedsBase

Idrofos ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.

Osteonecrosis of the jaw (ONJ)
All bisphosphonates carry ONJ risk — higher with IV agents (zoledronic acid, ibandronate IV) and longer cumulative therapy. Pre-treatment dental review is mandatory; complete invasive dentistry before starting. Avoid invasive dental procedures during therapy if possible. Notify dentist about bisphosphonate use lifelong (effects persist years after stopping).

Renal monitoring + adequate hydration
Bisphosphonates are renally cleared. Adequate hydration before/during IV administration. Monitor renal function and serum calcium. Hypocalcaemia is common; supplement with calcium + vitamin D throughout therapy. Avoid in CrCl <30 (oral) or <35 (IV).

Oral dosing rule (if oral)
Take first thing in the morning with a full glass (200 mL) of plain water — NO food, drink, or other medications. Remain upright (sitting or standing) for at least 30-60 minutes after the dose to prevent oesophagitis and oesophageal stricture. Then have breakfast and any other medications.

Frequently Asked Questions

When is this used?

Bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia (zoledronic acid IV is fastest), Paget’s disease, and severe osteoporosis (especially adjuvant during AI therapy in breast cancer).

IV vs oral?

IV (zoledronic acid 4 mg q3-4 weekly for cancer; q12 monthly for osteoporosis; ibandronate 6 mg q3-4 weekly): more potent, fewer doses, no GI absorption issues. Oral (ibandronate 150 mg monthly): convenient, no IV access needed, but oesophagitis risk and absorption issues.

ONJ — how worried should I be?

ONJ is rare but cumulative. Risk factors: invasive dental procedures (extraction, implants), poor dental hygiene, smoking, diabetes, glucocorticoid use. Pre-treatment dental review and ongoing oral hygiene minimise risk. Discuss any planned dental work with your oncology team.

Calcium and vitamin D?

Mandatory throughout bisphosphonate therapy: calcium 1000-1500 mg/day plus vitamin D 800-1000 IU/day. Reduces hypocalcaemia risk and improves bone density.

Drug interactions?

Calcium, magnesium, aluminium-containing antacids, iron, multivitamins reduce absorption (oral) — separate by ≥30 minutes. NSAIDs + bisphosphonates: increased GI risk. Aminoglycosides + bisphosphonates: increased nephrotoxicity.

Pregnancy?

Long half-life in bone (years to decades). Generally avoided in pre-menopausal women without effective contraception. Limited human pregnancy data.

What if I miss a dose?

Oral monthly: take next morning if remembered the same week; if missed entirely, return to the original schedule next month. IV: scheduled by specialist; reschedule with oncology team.

Atypical femoral fracture?

Rare class effect after long-term use (typically >5 years osteoporosis use). Drug holiday at 3-5 years considered in osteoporosis. Cancer use typically continues based on disease state.

Acute phase reaction?

Common after first IV bisphosphonate dose: fever, myalgia, arthralgia, fatigue 1-3 days post-infusion. Usually mild, paracetamol-responsive, less severe with subsequent doses.

Stopping?

Specialist-determined based on disease, response, toxicity. Bisphosphonate effect on bone persists for years after stopping due to bone deposition.

Other Cancer & Bone-Health Medications

Zoldria — zoledronic acid IV — for bone mets and hypercalcaemia
Bandrone — ibandronate — alternative bisphosphonate
Idrofos — ibandronate 150 mg monthly oral
Osteofos — alendronate weekly — for osteoporosis
Calcirol — vitamin D3 60,000 IU sachet — for adequacy

Medical Disclaimer: Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.